Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin treatment of collagenous colitis
2018-001891-39Phase 2Completed
- Sponsor
- XiCoCo Study Group
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in collagenous colitis (CC) comparing Budesonide + rifaximin with Budesonide + placebo (2 arms). Primary endpoint: Clinical remission at 12 weeks after budesonide cessation. Started Aug 2018; status: completed.
02
Drugs
rifaximin
03
Conditions
collagenous colitis (CC)
Beyond the preview
Go deeper on 2018-001891-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001891-39.